TodayBuildContextBrowseMore
stackBETAv0.1
TodayBuild a stackCommon stacksEncyclopediaPulse
Methodology
← Back to your stack
Monograph
RESEARCH GREYP-060
Longevity

Urolithin A

Postbiotic produced when gut microbiome metabolizes ellagitannins (from pomegranate, walnuts, berries). Activates mitophagy — the selective clearance of damaged mitochondria. Timeline is weeks, not days.

EmergingLongevity
Typical dose500–1000 mg
Frequencydaily, oral
Half-life10h
Citations indexed89
DeliveryOral
Half-life~10h
EvidenceEmerging
Citations89
Similar compounds
Synergy checkCompare
Research grey

This compound sits in research-grey territory. The caveats below carry more weight than for FDA-approved entries — read them.

Mechanism

The Amazentis (Timeline Nutrition) compound. Phase 2 RCT (Andreux 2019) showed improved mitochondrial gene expression and muscle function in older adults. The Olympia supplement delivers standardized 500 mg directly — bypassing the gut microbiome conversion step that only ~30% of people can do from dietary sources.

Specifics
Mitochondrial energy declineCellular aging concernsJoint pain
Caveats

Relatively new to market — most evidence is from the Amazentis-funded trial (industry funding). Long-term safety in humans not established. Premium pricing ($60–90/month) for ~3–4 months before effects are measurable.

Evidence levelEmerging
Regulatory statusDietary supplement (novel food in EU — requires approval per country).
DNA / pharmacogenomicsLow — Gut microbiome composition (not DNA) determines natural production capacity.
Claims & evidence

Per-claim grading. Each claim is graded independently — same peptide, different claims can carry different grades.

  • CLimited evidence

    Urolithin A — primary mechanism: postbiotic produced when gut microbiome metabolizes ellagitannins (from pomegranate, walnuts, berries). activates mitophagy — the selective clearance of damaged mitochondria. timeline is weeks, not days.

    2 supporting referencesVerified 5d ago
References

External links to PubMed searches, ClinicalTrials.gov, and FDA materials. We do not host papers — we point at canonical sources.

  • PubMedEN
    REVIEWFunding undisclosedVerified 5d ago
    Andreux 2019 — Urolithin A Phase 2 RCT
  • Clinical trialEN
    RCTFunding undisclosedVerified 5d ago
    ClinicalTrials — Urolithin A
RESEARCH GREYP-060

Dietary supplement (novel food in EU — requires approval per country).

Urolithin A500–1000 mg · daily, oral
Discussion guide, not prescription

stack is an exploration engine. Output is a discussion guide for a conversation with a licensed provider — never a prescription, dose recommendation, or sourcing instruction. Peptides discussed include compounds with limited human evidence and varying legal status by jurisdiction. Verify everything with a qualified clinician before any decision.

Full terms →
stackv0.1
AudiencesWho Stack is forFor researchersFor pharmaciesFor cliniciansFor press
Trust & regulatoryCalibrationMethodologyFDA statusPharmacy registryPCAC commentMX · COFEPRIS
Built honest. Bilingual from day one.